Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.50 USD
Change Today +0.15 / 4.48%
Volume 1.9K
DDXS On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
As of 5:19 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

diadexus inc (DDXS) Snapshot

Open
$3.35
Previous Close
$3.35
Day High
$3.50
Day Low
$3.35
52 Week High
01/8/15 - $10.65
52 Week Low
08/14/15 - $3.10
Market Cap
13.4M
Average Volume 10 Days
4.9K
EPS TTM
$-2.22
Shares Outstanding
3.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIADEXUS INC (DDXS)

Related News

No related news articles were found.

diadexus inc (DDXS) Related Businessweek News

No Related Businessweek News Found

diadexus inc (DDXS) Details

diaDexus, Inc., a life sciences company, focuses on the development and commercialization of cardiovascular diagnostic products addressing needs in cardiovascular disease. Its products include PLAC ELISA Test and the PLAC Activity Test that are designed to provide information on traditional risk factors, such as cholesterol levels to help identify individuals at risk of suffering a heart attack or stroke. The company’s PLAC ELISA Test is an aid in predicting risk for coronary heart disease (CHD) and ischemic strokes associated with atherosclerosis; and PLAC Test for Lp-PLA2 (lipoprotein-associated phospholipase A2) Activity is used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of CHD in patients with no prior history of cardiovascular events. Its pipeline of proprietary biomarkers comprises proADM, proET-1, and proANP for the treatment of heart failure diseases. The company markets its products to various national and regional clinical reference laboratories in the United States, Europe, and internationally. diaDexus, Inc. has a collaboration agreement with Mayo Clinic for the research and innovation of the PLAC(r) test for Lp-PLA2 activity. The company is headquartered in South San Francisco, California.

41 Employees
Last Reported Date: 03/12/15

diadexus inc (DDXS) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $100.0K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $431.8K
Chief Medical Officer
Total Annual Compensation: $117.5K
Compensation as of Fiscal Year 2014.

diadexus inc (DDXS) Key Developments

Diadexus, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015; Rescinds Revenue Guidance for 2015

Diadexus, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $4,571,000, loss from operations of $2,886,000, loss before income tax of $3,345,000, net loss of $3,348,000 or $0.87 per basic and diluted share compared to the total revenues of $7,676,000, loss from operations of $249,000, loss before income tax of $441,000, net loss of $441,000 or $0.12 per basic and diluted share for the same quarter a year ago. The decrease in total revenues is primarily attributable to lower PLAC ELISA product sales and a decrease in service revenues related to a GSK agreement which completed during the fourth quarter of 2014. For the six months period, the company reported total revenues of $10,098,000, loss from operations of $3,394,000, loss before income tax of $4,304,000, net loss of $4,318,000 or $1.13 per basic and diluted share compared to the total revenues of $13,111,000, loss from operations of $4,117,000, loss before income tax of $4,529,000, net loss of $4,541,000 or $1.24 per basic and diluted share for the same period a year ago. The decrease in total revenues is primarily due to lower PLAC ELISA product sales and a decrease in service revenues related to a GSK agreement, which completed during the fourth quarter of 2014. Due to the Health Diagnostics Laboratory bankruptcy, and the accompanying uncertainty around their ongoing business operations, the company is rescinding its previously stated revenue guidance for 2015. The Company will not be providing an outlook for 2015 at this time.

Diadexus, Inc., Q2 2015 Earnings Call, Aug 13, 2015

Diadexus, Inc., Q2 2015 Earnings Call, Aug 13, 2015

Diadexus, Inc. to Report Q2, 2015 Results on Aug 13, 2015

Diadexus, Inc. announced that they will report Q2, 2015 results After-Market on Aug 13, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DDXS:US $3.50 USD +0.15

DDXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.29 USD -0.73
Alere Inc $51.97 USD -0.78
Quest Diagnostics Inc $67.80 USD -1.09
Roche Holding AG SFr.264.00 CHF +0.80
Siemens AG €88.37 EUR +0.024
View Industry Companies
 

Industry Analysis

DDXS

Industry Average

Valuation DDXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIADEXUS INC, please visit www.diadexus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.